GlassScriptPhysician profile
Pamela L Meyer
NPI 1578648846
$9,900.01
in general payments reported to CMS, 2019-2025
33 companies · $1,820 in 2025
The $1,820 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,079 · 2020: $788 · 2021: $373 · 2022: $1,523 · 2023: $1,929 · 2024: $2,387 · 2025: $1,820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,868 · Education: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,867.96 |
| Education | $267.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,213.77 | 2019-2025 | Tremfya, Remicade, Stelara |
| Abbvie INC. | $1,299.12 | 2019-2025 | |
| Amgen INC. | $820.99 | 2021-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $569.40 | 2019-2025 | Ilumya, Winlevi |
| Ucb, INC. | $444.92 | 2019-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $417.09 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $410.79 | 2019-2025 | Dupixent, Libtayo |
| Revance Therapeutics, INC. | $335.96 | 2024-2025 | Daxxify |
| Galderma Laboratories, L.P. | $299.04 | 2019-2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $280.81 | 2019-2025 | |
| Leo Pharma INC. | $217.79 | 2019-2025 | Anzupgo |
| Merz North America, INC. | $216.82 | 2022-2023 | Xeomin |
| Vyne Pharmaceuticals INC. | $154.59 | 2020-2021 | |
| Janssen Scientific Affairs, LLC | $131.33 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.48 | 2022-2025 | Spevigo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $108.68 | 2019-2025 | Valchlor |
| Pfizer INC. | $106.08 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $102.22 | 2019-2020 | |
| Genentech USA, INC. | $94.79 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $78.14 | 2023-2025 | Zoryve |
| Strata Skin Sciences, INC. | $74.93 | 2023-2025 | Xtrac |
| Organon LLC | $73.64 | 2025 | Vtama |
| Dermavant Sciences, INC. | $70.95 | 2022-2024 | Vtama |
| Lilly USA, LLC | $67.41 | 2022-2023 | Olumiant, Taltz |
| Incyte Corporation | $43.84 | 2022-2023 | Opzelura |
| Genzyme Corporation | $33.83 | 2019-2020 | |
| Verrica Pharmaceuticals INC. | $30.12 | 2024 | Ycanth |
| Encore Dermatology INC. | $19.22 | 2019 | |
| Mayne Pharma Commercial LLC | $16.82 | 2019 | |
| Dusa Pharmaceuticals, INC. | $15.43 | 2019 | |
| Merck Sharp & Dohme LLC | $14.83 | 2019 | |
| Journey Medical Corporation | $11.84 | 2019 | |
| Prugen, INC. Pharmaceuticals | $11.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.